MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Cytokinetics Inc

Gesloten

SectorGezondheidszorg

40.38 0.22

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

39.4

Max

42

Belangrijke statistieken

By Trading Economics

Inkomsten

11M

-150M

Verkoop

16M

17M

EPS

-1.26

Winstmarge

-886.276

Werknemers

498

EBITDA

13M

-125M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+102.24% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-723M

5.1B

Vorige openingsprijs

40.16

Vorige sluitingsprijs

40.38

Nieuwssentiment

By Acuity

20%

80%

41 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Cytokinetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2024, 15:26 UTC

Acquisities, Fusies, Overnames

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 jun 2024, 14:14 UTC

Acquisities, Fusies, Overnames

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Peer Vergelijking

Prijswijziging

Cytokinetics Inc Prognose

Koersdoel

By TipRanks

102.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 81.4 USD  102.24%

Hoogste 120 USD

Laagste 62 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cytokinetics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

18 ratings

17

Buy

1

Hold

0

Sell

Technische score

By Trading Central

37.46 / 42.705Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

41 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.